image
Healthcare - Biotechnology - NASDAQ - US
$ 1.765
-3.33 %
$ 49 M
Market Cap
-1.96
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GANX stock under the worst case scenario is HIDDEN Compared to the current market price of 1.76 USD, Gain Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GANX stock under the base case scenario is HIDDEN Compared to the current market price of 1.76 USD, Gain Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one GANX stock under the best case scenario is HIDDEN Compared to the current market price of 1.76 USD, Gain Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GANX

image
$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-20.4 M OPERATING INCOME
8.55%
-20.4 M NET INCOME
8.34%
-18.9 M OPERATING CASH FLOW
-0.04%
4.98 M INVESTING CASH FLOW
-51.31%
13 M FINANCING CASH FLOW
2.93%
0 REVENUE
0.00%
-3.33 M OPERATING INCOME
25.29%
-3.77 M NET INCOME
15.99%
-3.45 M OPERATING CASH FLOW
43.14%
-43.4 K INVESTING CASH FLOW
-4344600.00%
2.31 M FINANCING CASH FLOW
186.00%
Balance Sheet Gain Therapeutics, Inc.
image
Current Assets 11.6 M
Cash & Short-Term Investments 10.4 M
Receivables 0
Other Current Assets 1.22 M
Non-Current Assets 521 K
Long-Term Investments 0
PP&E 323 K
Other Non-Current Assets 198 K
85.66 %10.03 %Total Assets$12.1m
Current Liabilities 3.91 M
Accounts Payable 946 K
Short-Term Debt 161 K
Other Current Liabilities 2.8 M
Non-Current Liabilities 873 K
Long-Term Debt 53.6 K
Other Non-Current Liabilities 819 K
19.78 %3.36 %58.61 %17.13 %Total Liabilities$4.8m
EFFICIENCY
Earnings Waterfall Gain Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 20.4 M
Operating Income -20.4 M
Other Expenses 60.6 K
Net Income -20.4 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)000(20m)(20m)(61k)(20m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-278.10% ROE
-278.10%
-168.36% ROA
-168.36%
-249.60% ROIC
-249.60%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Gain Therapeutics, Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)(20m)(20m)20192019202020202021202120222022202320232024202420252025
Net Income -20.4 M
Depreciation & Amortization 84.1 K
Capital Expenditures -22.5 K
Stock-Based Compensation 2.39 M
Change in Working Capital -1.08 M
Others -1.21 M
Free Cash Flow -18.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Gain Therapeutics, Inc.
image
GANX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Gain Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
64.5 K USD 2
6-9 MONTHS
20.7 K USD 1
9-12 MONTHS
7. News
Gain Therapeutics Announces Poster Presentation at AD/PD 2025 BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson's disease will be presented at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria. globenewswire.com - 1 month ago
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 globenewswire.com - 1 month ago
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the dosing of the first participant with Parkinson's disease (PD) in its Phase 1b clinical trial of GT-02287, the Company's lead allosteric small molecule in development for the treatment of PD with or without a GBA1 mutation. globenewswire.com - 1 month ago
Gain Therapeutics Announces Oral Presentation at AD/PD 2025 BETHESDA, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Joanne Taylor, Ph.D., Senior Vice President of Research at Gain, will give an oral presentation on the Company's clinical stage lead drug candidate GT-02287 at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria. globenewswire.com - 1 month ago
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company's President and CEO, Gene Mack: globenewswire.com - 2 months ago
Gain Therapeutics To Participate in Upcoming Investor Conferences BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Executive Officer of Gain, will present at two upcoming investor conferences: globenewswire.com - 2 months ago
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 months ago
Best Momentum Stocks to Buy for January 9th GANX, FHB and TRV made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024. zacks.com - 3 months ago
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson's disease, with potential for substantial market impact and investor gains. The drug's ability to restore GCase function and its positive preclinical and Phase 1 results highlight its potential as a best-in-class treatment. Gain's aggressive development strategy and strong data sharing indicate confidence, with Phase 1b trial results expected by mid-2025, potentially increasing the company's valuation. seekingalpha.com - 4 months ago
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT-02287 in people diagnosed with Parkinson's disease Phase 1b clinical trial follows successful Phase 1 study in which GT-02287 was safe and well tolerated while demonstrating GCase target engagement BETHESDA, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it has received approval in Australia to initiate a Phase 1b trial. globenewswire.com - 4 months ago
Gain Therapeutics To Present At Biotech Showcase 2025 Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform globenewswire.com - 4 months ago
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson's Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson's Disease Models GT-02287 Prevents Tau Accumulation in a Cellular Model BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of new evidence supporting the disease-modifying activity of GT-02287 in preclinical animal models of both GBA-1 and idiopathic Parkinson's disease during a late-breaker poster session yesterday at the Society for Neuroscience (SfN) 2024 conference that is being held October 5-9 in Chicago, IL. globenewswire.com - 6 months ago
8. Profile Summary

Gain Therapeutics, Inc. GANX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 49 M
Dividend Yield 0.00%
Description Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Contact 4800 Montgomery Lane, Bethesda, MD, 20814 https://www.gaintherapeutics.com
IPO Date March 19, 2021
Employees 23
Officers Dr. Jonas Hannestad M.D., Ph.D. Chief Medical Officer Dr. Terenzio Ignoni Pharm.D. Senior Vice President of Technical Operations Mr. Gene Mack M.B.A. President, Chief Executive Officer & Director Dr. Joanne Taylor Ph.D. Senior Vice President of Research Mr. Gianluca Fuggetta Senior Vice President of Finance & Principal Financial Officer Dr. Khalid Islam Ph.D. Executive Chairman